Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Regeneron and Teva will partner on the development and commercialization of the late-stage nerve growth factor antibody fasinumab for pain in a deal that will help Regeneron fund a 10,000-patient safety database.
You may also be interested in...
The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.
According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.